Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838

The phosphoinositide 3-kinase pathway

Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621

Protein kinases and phosphatases: The Yin and Yang of protein phosphorylation and signaling

Hunter, T. R. (1995) · Cell · doi:10.1016/0092-8674(95)90405-0 · Cited by 2,961

Phosphatidylinositol-3-OH kinase direct target of Ras

Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954

Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome

Tartaglia, M., Mehler, E. L., Goldberg, R. B., Zampino, G., Brunner, H. G., Kremer, H., van der Burgt, I., Crosby, A. H., Ion, A., Jeffery, S., et al. (2001) · Nature Genetics · doi:10.1038/ng772 · Cited by 1,736

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689

The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review)

Ardito, F., Giuliani, M., PERRONE, D., Troiano, G., & Muzio, L. L. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3036 · Cited by 1,437

Immune checkpoint signaling and cancer immunotherapy

He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,431

Regulation of JAK–STAT signalling in the immune system

Shuai, K., & Liu, B. (2003) · Nature reviews. Immunology · doi:10.1038/nri1226 · Cited by 1,410

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445

Small molecule inhibitors targeting the cancers

Liu, G., Chen, T., Zhang, X., Ma, X., & Shi, H. (2022) · MedComm · doi:10.1002/mco2.181 · Cited by 212

Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers

Dillon, M., Lopez, A. R., Lin, E., Sales, D., Perets, R., & Jain, P. (2021) · Cancers · doi:10.3390/cancers13205059 · Cited by 175

Targeting protein phosphatases for the treatment of inflammation-related diseases: From signaling to therapy

Pan, J., Zhou, L., Zhang, C., Xu, Q., & Sun, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01038-3 · Cited by 118

Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy

Song, Y., Wang, S., Zhao, M., Yang, X., & Yu, B. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02008 · Cited by 101

Quercetin as a JAK–STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases

Zalpoor, H., Nabi‐Afjadi, M., Forghaniesfidvajani, R., Tavakol, C., Farahighasreaboonasr, F., Pakizeh, F., Dana, V. G., & Seif, F. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00355-3 · Cited by 84

Immune Checkpoint Receptors Signaling in T Cells

Baldanzi, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073529 · Cited by 74

Discovery of ML210-Based glutathione peroxidase 4 (GPX4) degrader inducing ferroptosis of human cancer cells

Wang, H., Wang, C., Li, B., Zheng, C., Liu, Z., Liu, Z., Zhang, L., & Xu, P. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115343 · Cited by 68

Harnessing the cyclization strategy for new drug discovery

Tang, K., Wang, S., Gao, W., Song, Y., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.09.022 · Cited by 59

PROTACs: Novel tools for improving immunotherapy in cancer

Li, S., Chen, T., Liu, J., Zhang, H., Li, J., Wang, Z. P., & Shang, G. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216128 · Cited by 54

Crystallographic landscape of SHP2 provides molecular insights for SHP2 targeted drug discovery

Song, Y., Yang, X., Wang, S., Zhao, M., & Yu, B. (2022) · Medicinal Research Reviews · doi:10.1002/med.21890 · Cited by 35

A New View of Activating Mutations in Cancer

Nussinov, R., Tsai, C., & Jang, H. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2125 · Cited by 36

Application of functional peptides in the electrochemical and optical biosensing of cancer biomarkers

Cao, Y., Zhou, L. Y., Fang, Z., Zou, Z., Zhao, J. T., Zuo, X., & Li, G. (2023) · Chemical Communications · doi:10.1039/d2cc06824a · Cited by 35

PTPN2, A Key Predictor of Prognosis for Pancreatic Adenocarcinoma, Significantly Regulates Cell Cycles, Apoptosis, and Metastasis

Kuang, W., Wang, X., Ding, J., Li, J., Ji, M., Chen, W., Wang, L., & Yang, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.805311 · Cited by 34

Tyrosine phosphatase PTPN11/SHP2 in solid tumors - bull’s eye for targeted therapy?

Chen, X., Keller, S. J., Hafner, P., Alrawashdeh, A. Y., Avery, T. Y., Norona, J., Zhou, J., & Ruess, D. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340726 · Cited by 38

Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance

Eshaq, A. M., Flanagan, T. W., Hassan, S.-Y., Asheikh, S. A. A., Al-Amoudi, W. A., Santourlidis, S., Hassan, S.-L., Alamodi, M. O., Bendhack, M. L., Alamodi, M. O., et al. (2024) · Cancers · doi:10.3390/cancers16152754 · Cited by 31

Small-Molecule PROTACs for Cancer Immunotherapy

Liu, Z., Zhang, Y., Xiang, Y., & Kang, X. (2022) · Molecules · doi:10.3390/molecules27175439 · Cited by 30

Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches

Tojjari, A., Saeed, A., Sadeghipour, A., Kurzrock, R., & Cavalcante, L. L. (2023) · Cancers · doi:10.3390/cancers15225384 · Cited by 31

Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer

Chen, X., Shu, C., Li, W., Hou, Q., Luo, G., Yang, K., & Wu, X. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00063 · Cited by 27

Recent applications of computational methods to allosteric drug discovery

Govindaraj, R. G., Thangapandian, S., Schauperl, M., Denny, R. A., & Diller, D. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1070328 · Cited by 30

Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules

Guo, Z., Duan, Y., Sun, K., Zheng, T., Liu, J., Xu, S., & Xu, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116579 · Cited by 26

Targeting phosphatases: From molecule design to clinical trials

Guo, M., Li, Z., Gu, M., Gu, J., You, Q., & Wang, L. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116031 · Cited by 23

Binding Free Energy Calculation Based on the Fragment Molecular Orbital Method and Its Application in Designing Novel SHP-2 Allosteric Inhibitors

Yuan, Z., Chen, X., Fan, S., Chang, L., Chu, L., Zhang, Y., Wang, J., Li, S., Xie, J., Jian-guo, H., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010671 · Cited by 22

Dihydrotanshinone I Inhibits the Proliferation and Growth of Oxaliplatin-Resistant Human HCT116 Colorectal Cancer Cells

Wang, M., Xiang, Y., Wang, R., Zhang, L., Zhang, H., Chen, H., Luan, X., & Chen, L. (2022) · Molecules · doi:10.3390/molecules27227774 · Cited by 21

Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors

Tang, K., Zhao, M., Wu, Y.-H., Wu, Q., Wang, S., Dong, Y., Yu, B., Song, Y., & Liu, H.-M. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114106 · Cited by 20

PTPN14 promotes gastric cancer progression by PI3KA/AKT/mTOR pathway

Li, H., Guan, B., Liu, S., Liu, H., Song, L., Zhang, G., Zhao, R., Zhou, C., & Gao, P. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05712-4 · Cited by 18

Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions

Zhong, J., Bai, H., Wang, Z., Duan, J., Zhuang, W., Wang, D., Wan, R., Xu, J., Fei, K., Ma, Z., et al. (2023) · Frontiers of Medicine · doi:10.1007/s11684-022-0976-4 · Cited by 19

Small-molecule Modulators Targeting SHP2 for Cancer Therapy

Chen, Y., Mi, D., & Li, Y. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220921093052 · Cited by 17

The efficacy and safety of PI3K and AKT inhibitors for patients with cancer: A systematic review and network meta-analysis

Zhang, Y., Xu, X., Yang, K., Wang, S., Zhang, T., Hui, F., Zheng, F., Geng, H., Xu, C., Xun, F., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176952 · Cited by 18

A pan-cancer analysis confirms PTPN11’s potential as a prognostic and immunological biomarker

Cao, Y., Duan, H., Su, A., Xu, L., & Lai, B. (2022) · Aging · doi:10.18632/aging.204171 · Cited by 15

Targeting undruggable phosphatase overcomes trastuzumab resistance by inhibiting multi-oncogenic kinases

Wang, L., Lin, Y., Yao, Z., Babu, N., Lin, W., Chen, C., Du, L., Cai, S., Pan, Y., Xiong, X., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101118 · Cited by 15

Design, Synthesis and Antitumor Activity of a Novel Class of SHP2 Allosteric Inhibitors with a Furanyl Amide-Based Scaffold

Zhu, C., Zhao, H., Yang, W., Chen, K., Liu, X., Yu, Y., Li, R., Tan, R., & Yu, Z. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01217 · Cited by 14

DeepPath: overcoming data scarcity for protein transition pathway prediction using physics-based deep learning

Pang, Y. T., Yang, L., Kuo, K. M., & Gumbart, J. C. (2026) · Chemical Science · doi:10.1039/d5sc08253f · Cited by 13

Discovery of TK-642 as a highly potent, selective, orally bioavailable pyrazolopyrazine-based allosteric SHP2 inhibitor

Tang, K., Wang, S., Feng, S., Yang, X., Guo, Y., Ren, X., Bai, L., Yu, B., Liu, H., & Song, Y. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.028 · Cited by 11

A comprehensive overview of the molecular features and therapeutic targets in BRAF V600E ‐mutant colorectal cancer

Gu, R., Fang, H., Wang, R., Dai, W., & Cai, G. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1764 · Cited by 14

Ferroptosis triggers anti-tumor immunity via promoting chaperone-mediated autophagic degradation of SHP2

Zhu, J., Li, X., Chen, W., Zuo, Z., Gong, Q., Hu, J., Huang, K., Liu, W., Gu, Y., Xu, Q., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103796 · Cited by 12

Interactions between modified fullerenes and proteins in cancer nanotechnology

Serda, M., Korzuch, J., Dreszer, D., Krzykawska-Serda, M., & Musioł, R. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103704 · Cited by 12

Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

Deng, Y., Ma, G., Vallega, K. A., Wang, D., Wang, M., Wang, C., Wang, S., Ramalingam, S. S., & Sun, S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00472-3 · Cited by 13

Tyrosine phosphatase SHP2 aggravates tumor progression and glycolysis by dephosphorylating PKM2 in gastric cancer

Wang, P., Han, Y., Pan, W., Du, J., Zuo, D., Ba, Y., & Zhang, H. (2024) · MedComm · doi:10.1002/mco2.527 · Cited by 12

Protein tyrosine phosphatase receptor type kappa (PTPRK) revisited: evolving insights into structure, function, and pathology

Chen, Z., Liu, T., Wang, A. Q., Chen, X., Zhang, R., Wang, X. C., Lv, C. Y., Pan, R. L., Wang, O. C., & Lu, X. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06496-1 · Cited by 13

Cathepsin K inhibition induces Raptor destabilization and mitochondrial dysfunction via Syk/SHP2/Src/OTUB1 axis-mediated signaling

Seo, S. U., Woo, S. M., & Kwon, T. K. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05884-z · Cited by 11

Protein Tyrosine Phosphatase Receptor-type Q: Structure, Activity, and Implications in Human Disease

Zhang, W., Tang, Z., Fan, S., Yao, D., Zhang, Z., Guan, C., Deng, W., & Ying, Y. (2022) · Protein and Peptide Letters · doi:10.2174/0929866529666220511141826 · Cited by 10

Combining EGFR Inhibitors With SHP2 Or LSD1 Inhibitors to Overcome Multidrug Resistance in Cancer

Zhang, H., Yang, X., Song, Y., & Yu, B. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0326 · Cited by 10

sPGGM: a sample-perturbed Gaussian graphical model for identifying pre-disease stages and signaling molecules of disease progression

Zhong, J., Li, J., Gu, X., Ding, D., Ling, F., Chen, P., & Liu, R. (2025) · National Science Review · doi:10.1093/nsr/nwaf189 · Cited by 10

Targeting SHP2: Dual breakthroughs in colorectal cancer therapy–from signaling pathway modulation to immune microenvironment remodeling

Liu, P., & Chen, J. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i7.107380 · Cited by 10

Setting sail: Maneuvering SHP2 activity and its effects in cancer

Welsh, C. L., Allen, S., & Madan, L. K. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.03.003 · Cited by 9

SH2db, an information system for the SH2 domain

Bajusz, D., Pándy‐Szekeres, G., Takács, Á., de Araujo, E. D., & Keserű, G. M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad420 · Cited by 9

WWP1 inhibition increases SHP2 inhibitor efficacy in colorectal cancer

Fan, H., Hu, X., Cao, F., Zhou, L., Wen, R., Shen, H., Fu, Y., Zhu, X., Jia, H., Liu, Z., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00650-6 · Cited by 9

Allosteric SHP2 inhibition enhances regorafenib's effectiveness in colorectal cancer treatment

Han, X., Wang, W., Wang, R., Zhang, W., Zhu, L., Xu, Q., Guo, W., & Gu, Y. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.149812 · Cited by 7

Therapeutic potential of targeting protein tyrosine phosphatases in liver diseases

Wang, A., Zhang, Y., Lv, X., & Liang, G. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.05.006 · Cited by 7

Toward a Treatment of Cancer: Design and In Vitro/In Vivo Evaluation of Uncharged Pyrazoline Derivatives as a Series of Novel SHP2 Inhibitors

Dai, J., Zhang, Y., Gao, Y., Bai, X., Liu, F., Li, S., Yu, Y., Hu, W., Shi, T., Shi, D., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073497 · Cited by 7

Enhancing KRAS G12D inhibitor sensitivity in pancreatic cancer through SHP2/PI3K pathway

Hao, M.-W., Zhang, T., Dong, D. F., Xin Min, Z. H. O. U., & Gao, H. (2025) · Medical Oncology · doi:10.1007/s12032-025-02683-8 · Cited by 6

Allosteric SHP2 inhibitors suppress lung cancer cell migration by inhibiting non-canonical activation of EphA2 via the ERK-RSK signaling pathway

Nguyen, K., Zhou, Y., Yokoyama, S., Sasaki, S., Yano, S., Hayashi, R., Koizumi, K., Hayakawa, Y., & Sakurai, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-20770-8 · Cited by 6

Phosphatase Dysregulation in Cancer: Signaling Pathways and Therapeutic Opportunities

Jama, M., Overduin, M., & Barakat, K. (2025) · MedComm – Oncology · doi:10.1002/mog2.70028 · Cited by 7

SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma

Zhou, P., Xiao, M., Li, W., Sun, X., Bai, Y., Meng, F., Zhu, Z., Yuan, W., & Sun, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.841308 · Cited by 7

Discovery of a novel SHP2 allosteric inhibitor using virtual screening, FMO calculation, and molecular dynamic simulation

Yuan, Z., Zhang, M., Chang, L., Chen, X., Ruan, S., Shi, S., Zhang, Y., Zhu, L., Li, H., & Li, S. (2024) · Journal of Molecular Modeling · doi:10.1007/s00894-024-05935-y · Cited by 6

Protein Tyrosine Phosphatases in Neuroblastoma: Emerging Roles as Biomarkers and Therapeutic Targets

Nunes‐Xavier, C. E., Zaldumbide, L., Mosteiro, L., Almaraz, R. L., de Andoín, N. G., Aguirre, P., Emaldi, M., Torices, L., Lopez, J. I., & Pulido, R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.811297 · Cited by 7

KRAS Q61H Mutation Confers Cancer Cells with Acquired Resistance to SHP2 Inhibition

Song, Y., Yang, X., & Yu, B. (2022) · Pharmaceutical Fronts · doi:10.1055/s-0042-1743411 · Cited by 6

Synthesis, fluorescence properties of novel thiazolo[3,2-b][1,2,4]triazol derivatives as potent SHP2 inhibitors and its uses in sensing for Fe3+ and cell imaging

Yan, X. F., Zhang, C., Gao, L., Cao, Z.-T., Gan, S., Li, J. X., Xiang, D.-J., Zhou, Y., & Wang, W. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.140960 · Cited by 6

Shp-1 regulates the activity of low-affinity T cells specific to endogenous self-antigen during melanoma tumor growth and drives resistance to immune checkpoint inhibition

Matous, J. G., Snook, J. P., Contreras, N. A., Ramstead, A. G., Charley, K. R., Kolawole, E. M., Kisiolek, J. N., Flint, K. A., Soedel, A. J., Robinson, B., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010879 · Cited by 5

Identification of new small molecule allosteric SHP2 inhibitor through pharmacophore-based virtual screening, molecular docking, molecular dynamics simulation studies, synthesis and in vitro evaluation

Mitra, R., Kumar, S., & Ayyannan, S. R. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2291733 · Cited by 6

Optimization of SHP2 allosteric inhibitors with novel tail heterocycles and their potential as antitumor therapeutics

Zhu, C., Li, L., Yu, Y., Wang, X., Shi, Y., Gao, Y., Chen, K., Liu, X., Cui, Y., Zhang, T., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117078 · Cited by 5

Targeting SHP2 with Natural Products: Exploring Saponin-Based Allosteric Inhibitors and Their Therapeutic Potential

Moon, D. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47050309 · Cited by 4

Pepsinogen C Interacts with IQGAP1 to Inhibit the Metastasis of Gastric Cancer Cells by Suppressing Rho-GTPase Pathway

Ding, H.-X., Liu, Y., Lü, X., Liu, A., Xu, Q., & Yuan, Y. (2024) · Cancers · doi:10.3390/cancers16101796 · Cited by 4

Dynamic responses during early development of the sea urchin Strongylocentrotus intermedius to CO2-driven ocean acidification: A microRNA-mRNA integrated analysis

Yin, W., Mai, W., Cui, D., Zhao, T., Song, J., Zhang, W., Chang, Y., & Zhan, Y. (2025) · Marine Pollution Bulletin · doi:10.1016/j.marpolbul.2024.117514 · Cited by 4

SHP2 is a multifunctional target in anaplastic thyroid carcinoma: Cell intrinsic and immune-dependent anti-tumor effects

Marotta, M., Zirpoli, S., Prevete, N., Simone, C. D., Cristofano, A. D., Liotti, F., & Melillo, R. M. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118384 · Cited by 4

Deletion of the tyrosine phosphatase Shp2 in cervical cancer cells promotes reprogramming of glutamine metabolism

Gao, X., Kang, J., Li, X., Chen, C., & Luo, D. (2023) · The FASEB Journal · doi:10.1096/fj.202202078rr · Cited by 4

High expression of SHP2 predicts a promising prognosis in colorectal cancer

Liu, X., Li, M., Chen, L., Wen, F., Zheng, S. S., & Ge, W. (2023) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_894_22 · Cited by 4

New indole-diterpenoids with protein tyrosine phosphatase inhibitory activity from a marine-derived fungus Penicillium janthinellum

Li, L., Qin, X.-X., Qin, Y., Wang, T., Liu, X.-M., Wang, X., Liu, Z., You, Z., & Cao, F. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.140428 · Cited by 5

SHP2 inhibition and adjuvant therapy synergistically target KIT‐mutant GISTs via ERK1/2‐regulated GSK3β/cyclin D1 pathway

He, C., Yu, J., Mao, S., Yang, S., Jiang, X., Huang, L., Li, M., He, Y., Zhang, X., & Xiang, X. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70231 · Cited by 3

Cheminformatic profiling of Azardirachta indica phytochemicals as dual SHP2/HSP90 oncogenic inhibitors: Identification of nimbocinol, nimbidinin, and margolone

Agboola, O. E., Ayinla, Z. A., Apalowo, O. E., Agboola, S. S., Fajana, O. M., Ekundayo, B. E., Itakorode, B. O., & Oyinloye, B. E. (2025) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2025.04.001 · Cited by 4

Molecular recognition of ITIM/ITSM domains with SHP2 and their allosteric effect

Yan, C., Ouyang, W., Liu, L., Tang, L., Zhang, Z., Yue, X., Liang, L., Hu, J., & Luo, T. L. (2023) · Physical Chemistry Chemical Physics · doi:10.1039/d3cp03923d · Cited by 4

Emerging Therapeutic Approaches of SHP2-Targeted Modulators

Yang, X., Xiong, J., Yu, B., & Song, Y. (2024) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0348 · Cited by 4

Study on SHP2 Conformational Transition and Structural Characterization of Its High-Potency Allosteric Inhibitors by Molecular Dynamics Simulations Combined with Machine Learning

Wujieti, B., Hao, M., Liu, E., Zhou, L., Wang, H., Zhang, Y., Cui, W., & Chen, B. (2024) · Molecules · doi:10.3390/molecules30010014 · Cited by 3

Comprehensive multi-omics analysis reveals the prognostic and immune regulatory characteristics of the PTPN family in osteosarcoma

Long, C., Ma, B., Zhong, X., Zou, M., Li, K., & Liu, S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326872 · Cited by 3

Destabilization of the SHP2 and SHP1 protein tyrosine phosphatase domains by a non-conserved “backdoor” cysteine

Yarnall, M. T. N., Kim, S., Korntner, S., & Bishop, A. C. (2022) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2022.101370 · Cited by 3

Mometasone Furoate Inhibits the Progression of Head and Neck Squamous Cell Carcinoma via Regulating Protein Tyrosine Phosphatase Non-Receptor Type 11

Qiu, L., Gao, Q., Tao, A., Jiang, J., & Li, C. (2023) · Biomedicines · doi:10.3390/biomedicines11102597 · Cited by 3

SHP2 inhibition reduces somatotroph tumor growth in a pre-clinical model

Barberá, F. G., Picech, F., Cecenarro, L. A., Mezger, G. F., Faure, E. E., Zlocowski, N., Calafat, P., Battista, J. C. D., Mukdsi, J. H., Sosa, L. D. V., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf057 · Cited by 2

Structure-Guided Design of Pyrazolopyrimidinones as Highly Potent and Selective Allosteric SHP2 Inhibitors

Song, Y., Ren, X., Yang, X., Xiong, J., Wang, W., Tang, K., & Yu, B. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00524 · Cited by 3

SHP2-targeted cancer therapeutics: Structural insights, inhibitor development and emerging modalities

Zhang, Y., Zhu, C., Si, C., Lin, Y., Guo, Q., Zhou, H., & Yu, Z. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118708 · Cited by 3

Targeting Protein Phosphatases for the Treatment of Chronic Liver Disease

Li, Y., He, H., & Zhang, N. (2024) · Current Drug Targets · doi:10.2174/0113894501278886231221092522 · Cited by 2

Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors

Sahu, P., Mitra, A., & Ganguly, A. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.01.005 · Cited by 2

Design, Synthesis and Evaluation of Thioacetamide‐Tethered Thiadiazole‐1,2,4‐Triazole Hybrids as SHP2 Inhibitors for Cancer Therapy

Mitra, R., Kumar, S., Chaudhuri, A., Agrawal, A. K., & Ayyannan, S. R. (2024) · ChemistrySelect · doi:10.1002/slct.202401602 · Cited by 3

SHP2 promotes the epithelial-mesenchymal transition in triple negative breast cancer cells by regulating β-catenin

Qian, S., Zhu, J., Han, Q., Cheng, H., & Zhou, H. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06097-x · Cited by 2

Inhibiting the Extracellular Signal-regulated Kinase 1/2 (ERK1/2) Cascade in Cancer and the Heart: for Better or Worse, in Sickness and Health?

Clerk, A., Amadi, S. U., Smith, S. J., & Sugden, P. H. (2024) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2024.100006 · Cited by 2

Discovery of 1H-pyrazolo[3,4- b ]pyrazine derivatives as selective allosteric inhibitor of protein tyrosine phosphatase SHP2 for the treatment of KRAS G12C -mutant non-small cell lung cancer

Xu, W.-Q., Qi, S., Zhao, J., Li, L., Ding, C., & Liu, W. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2308771 · Cited by 1

Lycii Radicis Cortex suppresses the growth of non-small cell lung cancer via enhancing the anti-tumor immunity

Yin, H., Liu, M., Zhao, Y., Wu, H., Zheng, D., Guo, Z., Zhou, Y., Wu, S., Chen, C., Zhang, L., et al. (2024) · Food Science and Human Wellness · doi:10.26599/fshw.2024.9250041 · Cited by 1

Design and Synthesis of S ‐Acetophenylhydrazones of 5‐Methyl‐1,3,4‐Thiadiazole‐2‐Thiol as SHP2 Inhibitory Agents

Mitra, R., Kumar, S., Chaudhuri, A., Majumdar, S., Krishnamurthy, S., Agrawal, A. K., & Ayyannan, S. R. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202402997 · Cited by 2

Dual-specificity phosphatases: Potential targets for cognitive impairment induced by chronic kidney disease

Liao, L., Hu, Q., Zhang, Y., Liao, J., Su, H.-W., Wu, A., Xu, T., & Wu, J. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114883 · Cited by 1

Structure-guided expansion strategy unveils potent allosteric SHP2 inhibitors with synergistic efficacy against AML through MCL-1 co-targeting

Zhang, M., Wu, S., Liu, M., Li, H., Wang, L., Duan, F., Han, R., Shan, C., Jiang, Z., Liao, J., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117988 · Cited by 1

PZR: Advances in research from cellular signaling Hub to emerging therapeutic targets

Wang, H. P., Sha, W., Fu, Y., & Wang, H. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.112061 · Cited by 1

Small-molecule drug discovery in malignant melanoma: current status and prospective developments

Miao, X., Liu, Y., Li, C., Wu, J., Li, Y., Li, Z., Li, J., Sun, Y., & Han, J. (2025) · Medicinal Chemistry Research · doi:10.1007/s00044-025-03515-0 · Cited by 1

Targeting PTPN22 at Nonorthosteric Binding Sites─A Fragment Approach

Lello, P. D., Wells, M. M., Davis, B. J., Daniels, Z., Garner, T. P., Gazzard, L. J., Harris, R., Hubbard, R. E., Landry, M. L., Martin, B. T., et al. (2026) · ACS Omega · doi:10.1021/acsomega.5c11028 · Cited by 1

Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2-amplified gastric cancer

Zhang, Y., Wang, H., Wei, Y., Pan, Y., Song, X., Shao, J., Yu, L., Shi, T., & Wang, Y. (2026) · eLife · doi:10.7554/elife.104060.3 · Cited by 1

Targeting SHP2 for Cancer Treatment: Advances and Prospects

Song, Y., & Yu, B. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_256-1 · Cited by 1

Discovery of Environment-Sensitive Near Infrared SHP2-Targeting Fluorescent Ligands for Living Cells and Tissue Section Imaging

Liang, D., Chen, Y., Yan, L., Guo, C., Zhang, Y., Chen, S., Du, L., Liu, A., Sun, D., Li, M., et al. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c00591 · Cited by 1

Novel Pyrazolopyrazine Compounds as SHP2 Inhibitors for Treating Glioblastoma

Sabnis, R. W. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00393 · Cited by 1

High expression of SHP2 predicts a promising prognosis in colorectal cancerPreprint

Liu, X., Li, M., Chen, L., Wen, F., Zheng, S. S., & Ge, W. (2022) · Research Square · doi:10.21203/rs.3.rs-1717423/v1

Research Progress in Allosteric SHP2 Inhibitors

堵, 桐. (2022) · Hans Journal of Medicinal Chemistry · doi:10.12677/hjmce.2022.102021

Exploring Allosteric Inhibitors of Protein Tyrosine Phosphatases Through High-Throughput Screening

Hayashi, T., & Hatakeyama, M. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3331-1_18

Complex Roles of PTPN11/SHP2 in Carcinogenesis and Prospect of Targeting SHP2 in Cancer Therapy

Scheiter, A., Lu, L., Gao, L. H., & Feng, G. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062722-013740 · Cited by 13

A comprehensive review of SHP2 and its role in cancer

Asmamaw, M. D., Shi, X.-J., Zhang, L.-R., & Liu, H.-M. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00698-1 · Cited by 119

Setting sail: Maneuvering SHP2 activity and its effects in cancer

Welsh, C. L., Allen, S., & Madan, L. K. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.03.003 · Cited by 9

SHP2-targeted cancer therapeutics: Structural insights, inhibitor development and emerging modalities

Zhang, Y., Zhu, C., Si, C., Lin, Y., Guo, Q., Zhou, H., & Yu, Z. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118708 · Cited by 3

Protein Tyrosine Phosphatase SHP-2 as Drug Target

Somani, R. R., Madan, D., & Rai, P. (2016) · Mini-Reviews in Organic Chemistry · doi:10.2174/1570193x13666161017141804 · Cited by 2